- Home
- BNTC vs CURR Comparison
BNTC vs CURR Comparison
Compare BNTC & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNTC
- CURR
- Stock Information
- Founded
- BNTC 1995
- CURR 2013
- Country
- BNTC United States
- CURR Singapore
- Employees
- BNTC N/A
- CURR N/A
- Industry
- BNTC Biotechnology: Pharmaceutical Preparations
- CURR Business Services
- Sector
- BNTC Health Care
- CURR Consumer Discretionary
- Exchange
- BNTC Nasdaq
- CURR Nasdaq
- Market Cap
- BNTC 88.1M
- CURR 89.8M
- IPO Year
- BNTC N/A
- CURR N/A
- Fundamental
- Price
- BNTC $10.68
- CURR $1.92
- Analyst Decision
- BNTC Strong Buy
- CURR
- Analyst Count
- BNTC 5
- CURR 0
- Target Price
- BNTC $22.60
- CURR N/A
- AVG Volume (30 Days)
- BNTC 33.8K
- CURR 10.1K
- Earning Date
- BNTC 11-14-2024
- CURR 11-26-2024
- Dividend Yield
- BNTC N/A
- CURR N/A
- EPS Growth
- BNTC N/A
- CURR N/A
- EPS
- BNTC N/A
- CURR N/A
- Revenue
- BNTC N/A
- CURR N/A
- Revenue This Year
- BNTC N/A
- CURR N/A
- Revenue Next Year
- BNTC N/A
- CURR N/A
- P/E Ratio
- BNTC N/A
- CURR N/A
- Revenue Growth
- BNTC N/A
- CURR N/A
- 52 Week Low
- BNTC $2.69
- CURR $1.70
- 52 Week High
- BNTC $12.89
- CURR $5.74
- Technical
- Relative Strength Index (RSI)
- BNTC 53.25
- CURR N/A
- Support Level
- BNTC $10.25
- CURR N/A
- Resistance Level
- BNTC $10.89
- CURR N/A
- Average True Range (ATR)
- BNTC 0.43
- CURR 0.00
- MACD
- BNTC -0.07
- CURR 0.00
- Stochastic Oscillator
- BNTC 69.39
- CURR 0.00
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants worldwide, delivering frictionless interoperable real-time fund transfers and instant messaging.